STACEY WRIGHT: Open Payments
NPI 1497716476 · GARDEN CITY, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,188 in 33 payments from 12 companies in 2025. Trend: 2023 $1,770 · 2024 $639 · 2025 $1,188
Food & beverage: $1,188
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $200 |
| Neurocrine BioSciences, Inc. | 3 | $178 |
| Teva Pharmaceuticals USA, Inc. | 4 | $169 |
| E.R. Squibb & Sons, L.L.C. | 3 | $156 |
| Janssen Pharmaceuticals, Inc | 2 | $138 |
| ABBVIE INC. | 3 | $136 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
Products named: INGREZZA, COBENFY, VRAYLAR, SPRAVATO, UZEDY, ABILIFY MAINTENA, REXULTI, FANAPT.
Industry payments across ID — which companies pay providers there.
